Pay in 4 interest-free payments of $5.81 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Please describe any additional due diligence procedures you have in place
Key Takeaways TRIUMPH-4 (obesity + knee osteoarthritis) reported 28.7% mean weight loss at 12 mg / 68 weeks TRANSCEND-T2D-1 reported HbA1c reductions up to 2.0%, read out March 19, 2026 A new safety signal dysesthesia (abnormal skin sensations) was observed at 20.9% incidence at the 12 mg dose NDA filing is expected Q4 2026
It has been shown to reduce body weight by 8-10% over 12 weeks, with participants showing decreases in BMI, waist circumference and fat mass
Waist circumference may be down 2-4 inches from baseline
In addition, we may perform laboratory tests, such as blood work or a lipid panel, to assess the patients overall health and determine if any underlying medical conditions may impact the effectiveness or safety of semaglutide
US$ 25.27
US$ 27.25
US$ 25.95
US$ 26.89
